RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and lowers the price target from $13 to $12.